HK1051651A1 - Epoxy-steroidal aldosterone antagonist and calciumchannel blocker combination therapy for treatment of congestive heart failure - Google Patents

Epoxy-steroidal aldosterone antagonist and calciumchannel blocker combination therapy for treatment of congestive heart failure

Info

Publication number
HK1051651A1
HK1051651A1 HK03103912A HK03103912A HK1051651A1 HK 1051651 A1 HK1051651 A1 HK 1051651A1 HK 03103912 A HK03103912 A HK 03103912A HK 03103912 A HK03103912 A HK 03103912A HK 1051651 A1 HK1051651 A1 HK 1051651A1
Authority
HK
Hong Kong
Prior art keywords
epoxy
combination therapy
treatment
heart failure
congestive heart
Prior art date
Application number
HK03103912A
Other languages
English (en)
Inventor
Joseph R Schuh
Susan Garthwaite
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of HK1051651A1 publication Critical patent/HK1051651A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK03103912A 2000-07-27 2003-06-02 Epoxy-steroidal aldosterone antagonist and calciumchannel blocker combination therapy for treatment of congestive heart failure HK1051651A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22135900P 2000-07-27 2000-07-27
PCT/US2001/023677 WO2002009761A2 (fr) 2000-07-27 2001-07-27 Polytherapie par antagoniste d'aldosterone epoxy-steroidien et inhibiteur calcique pour le traitement de l'insuffisance cardiaque congestive

Publications (1)

Publication Number Publication Date
HK1051651A1 true HK1051651A1 (en) 2003-08-15

Family

ID=22827483

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03103912A HK1051651A1 (en) 2000-07-27 2003-06-02 Epoxy-steroidal aldosterone antagonist and calciumchannel blocker combination therapy for treatment of congestive heart failure

Country Status (10)

Country Link
US (2) US20020042405A1 (fr)
EP (1) EP1303305B1 (fr)
JP (1) JP2004505061A (fr)
AT (1) ATE357257T1 (fr)
AU (2) AU7804501A (fr)
CA (1) CA2415826A1 (fr)
DE (1) DE60127410T2 (fr)
ES (1) ES2281431T3 (fr)
HK (1) HK1051651A1 (fr)
WO (1) WO2002009761A2 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040048780A1 (en) * 2000-05-10 2004-03-11 The Trustees Of Columbia University In The City Of New York Method for treating and preventing cardiac arrhythmia
US20040229781A1 (en) * 2000-05-10 2004-11-18 Marks Andrew Robert Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
US6489125B1 (en) * 2000-05-10 2002-12-03 The Trustees Of Columbia University In The City Of New York Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor
US7718644B2 (en) * 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US7879840B2 (en) * 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US20060293266A1 (en) * 2000-05-10 2006-12-28 The Trustees Of Columbia Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7393652B2 (en) * 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US6852737B2 (en) * 2001-08-06 2005-02-08 Recordati Ireland Limited Crude and crystalline forms of lercanidipine hydrochloride
US20040242565A1 (en) * 2001-09-11 2004-12-02 Yoshinori Toshima Medicinal composition for prevention of or treatment for cerebrovascular disorder and cardiopathy
US8822473B2 (en) 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
BR0311161A (pt) 2002-05-21 2005-03-29 Cv Therapeutics Inc Método de tratamento de diabetes
US7544678B2 (en) * 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
RU2294328C2 (ru) 2002-12-24 2007-02-27 Санкио Компани, Лимитед Оптически активные производные дигидропиридина, их применение и терапевтическое средство на их основе
ATE437641T1 (de) * 2003-05-15 2009-08-15 Roskamp Res Llc Verfahren zur herstellung von medikamenten zur verringerung der amyloid-abscheidung, amyloid- neurotoxizität und mikrogliosis
CA2536764C (fr) * 2003-08-25 2013-09-17 Newron Pharmaceuticals, S.P.A. Derives d'.alpha.-aminoamide utilisables comme agents anti-inflammatoires
US8710045B2 (en) * 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US20080194669A1 (en) * 2004-08-20 2008-08-14 Gray Lloyd S T Type Calcium Channel Blockers and the Treatment of Diseases
US20100222406A1 (en) * 2007-09-11 2010-09-02 University Of Virginia Patent Foundation T Type Calcium Channel Blockers and the Treatment of Diseases
US7704990B2 (en) * 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
TWI387592B (zh) * 2005-08-30 2013-03-01 Novartis Ag 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
US8251998B2 (en) * 2006-08-16 2012-08-28 Biomet Sports Medicine, Llc Chondral defect repair
AU2007335192A1 (en) * 2006-12-21 2008-06-26 Alphapharm Pty Ltd Pharmaceutical composition
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
WO2008101012A1 (fr) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Utilisation de la ranolazine pour le traitement de maladies microvasculaires non coronariennes
CA2678319A1 (fr) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Utilisation de la ranolazine dans le traitement des maladies microvasculaires coronaires
CA2678272A1 (fr) * 2007-02-13 2008-10-02 Cv Therapeutics, Inc. Utilisation de la ranolazine pour le traitement de maladies cardiovasculaires
WO2008116083A1 (fr) * 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Utilisation de ranolazine contre un taux élevé de peptide natriurétique de type b
US20080299195A1 (en) * 2007-05-31 2008-12-04 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
US20100093810A1 (en) * 2007-10-05 2010-04-15 Alzheimer's Institute Of America, Inc. Pharmaceutical Compositions for Reducing Amyloid Deposition, Amyloid Neurotoxicity, and Microgliosis
CN101883564B (zh) * 2007-10-05 2013-10-16 阿尔茨海默病学会美国公司 使用(-)-尼伐地平对映体减少淀粉状蛋白沉积、淀粉状蛋白神经毒性和小神经胶质增生的方法
ES2613804T3 (es) 2008-07-17 2017-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Inhibidores de MRP4 y agentes que estimulan la actividad de MRP4 para el tratamiento de trastornos cardíacos
TWI508726B (zh) * 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
KR101821343B1 (ko) 2010-03-01 2018-01-23 타우 쎄라퓨틱스 엘엘씨 암 진단 및 영상화
CN108727453A (zh) * 2017-04-20 2018-11-02 华东理工大学 新型pd-1抑制剂及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1142793C (zh) * 1995-06-07 2004-03-24 G·D·瑟尔公司 环氧-甾族化合物醛甾酮拮抗剂和血管紧张肽ⅱ拮抗剂联合治疗用于治疗充血性心衰
AU6039296A (en) * 1995-06-07 1996-12-30 G.D. Searle & Co. Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldoste rone antagonist
CZ20011590A3 (cs) * 1998-11-06 2003-01-15 G. D. Searle & Co. Léčivo pro léčení kardiovaskulárních poruch a kompozice s obsahem inhibitoru enzymu konvertujícího angiotensin, antagonisty aldosteronu, kličkového diuretika a digoxinu
US20020132001A1 (en) * 2000-05-11 2002-09-19 Garthwaite Susan M. Aldosterone antagonist composition for release during aldosterone acrophase

Also Published As

Publication number Publication date
US20030055027A1 (en) 2003-03-20
AU7804501A (en) 2002-02-13
US20020042405A1 (en) 2002-04-11
WO2002009761A2 (fr) 2002-02-07
AU2001278045B2 (en) 2006-08-03
ATE357257T1 (de) 2007-04-15
JP2004505061A (ja) 2004-02-19
ES2281431T3 (es) 2007-10-01
EP1303305A2 (fr) 2003-04-23
EP1303305B1 (fr) 2007-03-21
WO2002009761A3 (fr) 2003-01-03
WO2002009761A9 (fr) 2003-07-10
DE60127410T2 (de) 2007-12-13
DE60127410D1 (de) 2007-05-03
CA2415826A1 (fr) 2002-02-07

Similar Documents

Publication Publication Date Title
AU7804501A (en) Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
WO2004082599A3 (fr) Combinaison d'un antagoniste de recepteur d'aldosterone et d'un agent anti-diabetique
AU7905001A (en) Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure
MXPA05010507A (es) Combinacion de un antagonista del receptor de aldosterona y un agente antiobesidad.
ATE216261T1 (de) Kombinationstherapie zur behandlung des kongestiven herzversagens mit spironolacton und angiotensin ii-antagonist
MY141559A (en) Triazole derivatives as tachykinin receptor antagonists
EA200400146A1 (ru) Замещённые анилиновые пиперидины в качестве селективных антагонистов mch
AU7584400A (en) Treatment of movement disorders by administration of 5-hydroxytryptamine receptor/alpha2 adrenergic receptor antagonist compositions
DK0831910T3 (da) Kombinationsterapi med epoxy-steroid aldosteronantagonist og angiotensin II-receptorantagonist til behandling af kongestivt hjertesvigt
PL369887A1 (en) Pharmaceutical nanoparticulate composition of a tachykinin receptor antagonist
WO2004017896A3 (fr) Traitement combine faisant intervenir un double agoniste de ppar alpha/gamma et un recepteur de type i d'angiotensine ii
JP2004511522A5 (fr)
BR0312256A (pt) Composto, composição farmacêutica, processo para a preparação de uma composição farmacêutica, e, método de tratamento de um indivìduo sofrendo de um distúrbio mediado pelo receptor de mch1 e de tratamento de um indivìduo sofrendo de depressão, ansiedade, incontinência de urgência ou obesidade
EA200000360A1 (ru) Оральные композиции левосимендана
AU1432402A (en) Medicinal compositions
EA200501122A1 (ru) Замещенные алкиламидопиперидины
WO2005040157A3 (fr) Nouveaux antagonistes des recepteurs de l'hormone mch
IL145645A0 (en) N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists
UA77025C2 (en) Tetrahydrocarbozole derivatives as ligands for g-protein coupled receptors (gpcr), a pharmaceutical composition and a method for preparation of compounds
MY118704A (en) Process for preparation of eprosartan
WO2002017899A3 (fr) Procede servant a reguler l'angiogenese
WO2003063846A3 (fr) Therapie utilisant une combinaison d'antagoniste du recepteur d'aldosterone et un agent modulateur alpha-adrenergique, destinee a la prevention ou au traitement d'etats pathogenes
WO2004080411A3 (fr) Antagonistes du recepteur de l'hormone concentrant la melanine et compositions et methodes associees
WO2003043640A3 (fr) Traitement de troubles depressifs majeurs au moyen d'antagonistes de recepteurs des glucocorticoides
EA200601315A1 (ru) 4-арилпиперидины

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: ADDITION OF INVENTOR: SUSAN GARTHWAITE

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20100727